+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tinnitus (Ear Nose Throat Disorders) - Drugs In Development, 2021

  • ID: 5402682
  • Report
  • July 2021
  • Region: Global
  • 63 Pages
  • Global Markets Direct
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • AudioCure Pharma GmbH
  • Auris Medical Holding Ltd
  • Autifony Therapeutics Ltd
  • Cognosetta Inc
  • Gateway Biotechnology Inc
  • Knopp Biosciences LLC
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Tinnitus - Drugs In Development, 2021, provides an overview of the Tinnitus (Ear Nose Throat Disorders) pipeline landscape.

Tinnitus is a condition characterized by ringing, swishing, or other noises that originating in the ear or head. Causes of tinnitus are age-related hearing loss, exposure to loud noises, earwax blockage in the ear canal, smoking and abnormal bone growth in the ear. Symptoms include ringing; buzzing, roaring, clicking, whistling, hissing, or squealing, noises may appear low or high in pitch.

Report Highlights


The publisher's Pharmaceutical and Healthcare latest pipeline guide Tinnitus - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Tinnitus (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tinnitus (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Tinnitus (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tinnitus (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tinnitus (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tinnitus (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tinnitus (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tinnitus (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AudioCure Pharma GmbH
  • Auris Medical Holding Ltd
  • Autifony Therapeutics Ltd
  • Cognosetta Inc
  • Gateway Biotechnology Inc
  • Knopp Biosciences LLC

Introduction
Tinnitus - Overview
  • Tinnitus - Therapeutics Development
Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Tinnitus - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Tinnitus - Companies Involved in Therapeutics Development
  • AudioCure Pharma GmbH
  • Auris Medical Holding Ltd
  • Autifony Therapeutics Ltd
  • Cognosetta Inc
  • Gateway Biotechnology Inc
  • Knopp Biosciences LLC
  • Otonomy Inc
  • Sensorion SA
Tinnitus - Drug Profiles
  • AC-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AM-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AUT-3 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CS-0022 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs for Tinnitus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • esketamine hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • gacyclidine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GW-103 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GW-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KB-3061 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RL-81 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate KCNQ2 and KCNQ3 for Tinnitus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tetrandrine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Tinnitus - Dormant ProjectsTinnitus - Discontinued ProductsTinnitus - Product Development Milestones
Featured News & Press Releases
  • Jun 16, 2021: Light E.N.T. announces first patient enrolled in drug trial for treatment of tinnitus (Ringing Sound in Ear)
  • Apr 05, 2021: Otonomy announces presentation of OTO-313 clinical results at American Neurotology Society Annual Meeting
  • Mar 25, 2021: Otonomy initiates phase 2 clinical trial of OTO-313 in Tinnitus
  • Nov 30, 2020: Otonomy provides update on OTO-313 program
  • Jul 06, 2020: Otonomy reports positive top-line results from phase 1/2 clinical trial of OTO-313 in patients with tinnitus
  • Jun 22, 2020: CogInc receives Bull Ring Accelerator Funding
  • Apr 08, 2020: CogInc awarded AOHL's Flexi grant
  • Jan 10, 2020: Auris Medical announces notice of allowance for European Patent Application
  • Dec 17, 2019: Cognosetta: SBIR grant awarded
  • Sep 13, 2019: Auris Medical receives FDA and EMA Guidance for Keyzilen late-stage clinical development program
  • Aug 26, 2019: Auris Medical announces formation of scientific advisory board for tinnitus programs
  • May 23, 2019: Auris Medical provides update on Keyzilen
  • Apr 25, 2019: Auris Medical provides update on Tinnitus Drug Development Strategy
  • Apr 11, 2019: Otonomy initiates phase 1/2 Clinical Trial of OTO-313 in Tinnitus
  • Feb 06, 2019: Otonomy announces presentation on tinnitus drug OTO-313 at Association for Research in Otolaryngology Annual Meeting
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development for Tinnitus, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Tinnitus - Pipeline by AudioCure Pharma GmbH, 2021
  • Tinnitus - Pipeline by Auris Medical Holding Ltd, 2021
  • Tinnitus - Pipeline by Autifony Therapeutics Ltd, 2021
  • Tinnitus - Pipeline by Cognosetta Inc, 2021
  • Tinnitus - Pipeline by Gateway Biotechnology Inc, 2021
  • Tinnitus - Pipeline by Knopp Biosciences LLC, 2021
  • Tinnitus - Pipeline by Otonomy Inc, 2021
  • Tinnitus - Pipeline by Sensorion SA, 2021
  • Tinnitus - Dormant Projects, 2021
  • Tinnitus - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Tinnitus, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AudioCure Pharma GmbH
  • Auris Medical Holding Ltd
  • Autifony Therapeutics Ltd
  • Cognosetta Inc
  • Gateway Biotechnology Inc
  • Knopp Biosciences LLC
  • Otonomy Inc
  • Sensorion SA
Note: Product cover images may vary from those shown